Nationwide, multicenter validation: AUC 0.95
Scroll to watch the AUC curve draw — the cited nationwide study reports an AUC of 0.95 across 1,473 CT studies.
Figure source: Radiology 2023 (220152) Fig. 3 — nationwide multicenter validation (n=1,473) |Article ↗
Every number, sourced
Six peer-reviewed publications, nine recognitions, and documented regulatory status in Taiwan and the United States.
International publications
6 peer-reviewed papers in Lancet Digital Health, Radiology and other top journals — real clinical validation led by National Taiwan University Hospital.
View 6 papersFDA Breakthrough Device
The U.S. FDA granted Breakthrough Device Designation to PANCREASaver®. This designation does not mean the device is FDA-cleared or available for U.S. marketing. FDA official program page ↗ Media coverage: FDA breakthrough designation ↗
TFDA medical device license (Taiwan)
Taiwan TFDA medical device license No. 007946.
Intellectual Property Portfolio
10 invention patents across Taiwan (6) and the U.S. (4), written at both system and method level, covering algorithms, imaging and clinical workflow.
View 10 patents9 national recognitions





From lab to clinic
Prof. Wang's team at NTU launches AI early detection research
Prof. Liao of NTUH leads multicenter clinical validation
PanCAD.ai founded; technology licensed for commercialization
First Margulis Award for Taiwan at RSNA
FDA Breakthrough Device Designation; Taiwan TFDA license No. 007946
Used across medical centers, regional hospitals, and health centers, with cumulative use in more than 5,500 patient cases across research and commercial applications
Every step, published
Lancet Digital Health
Multicenter validation of AI-assisted pancreatic CT review
Radiology
Deep learning for pancreatic lesion detection on CT
Other international journals
6 papers total, covering algorithms, clinical validation and workflow
Seamless with your existing systems
From assessment to go-live, four steps — we walk with you all the way.
Needs assessment
We review your imaging equipment, IT systems and clinical workflow to define scope.
System integration
Interface with PACS/RIS; AI results flow back automatically within the institution’s workflow.
Validation & training
Training for radiologists and technologists, plus validation on your institutional data.
Go-live & follow-up
Continuous performance monitoring, regular statistical reports and technical support.
What leading editors say about the science
Verbatim third-party statements on the peer-reviewed studies behind PANCREASaver®. Quotes are about the research — not the product — and each carries its original source.
“
…accurate detection of pancreatic cancer on CT scans, especially for tumors smaller than 2 cm. Early detection… greatly increases the chances of survival.
“
This deep learning–based tool had very good accuracy, and sensitivity approaching that of subspecialist radiologists… Tools such as this promise to benefit routine workflow and patient care.
“
These promising results show that CNN as a second reader can reduce misdiagnosis of pancreatic cancer and possibly lead to improved patient outcomes.
Ready to make AI part of your team?
Book a 30-minute technical briefing — we'll come with real data.
Book a briefing